Medtronic made waves in 2013 by moving beyond devices; Solona wins FDA clearance for a new orthopedic implant;

@FierceMedDev: Baxter nails a CE mark for next-generation home hemodialysis. More | Follow @FierceMedDev

@MarkHFierce: More problems for 23andMe--two women are suing the company over its test claims. Article | Follow @MarkHFierce

@MichaelGFierce: 'Walking' DNA motor on nanotube tracks could someday deliver drugs. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: FDA approves Philips' spectrometry for dense breasts in cancer screenings. Story | Follow @GalenMoore

> Medtronic ($MDT) is noted as having made waves in 2013 for being one of the first medical device companies to try to move beyond medical devices and more actively into healthcare services. Story

> Solona Surgical gained FDA clearance for a new implant that orthopedic and podiatric surgeons can use in foot and ankle procedures, and a rollout is planned for the 2014 first quarter. Item

> Reverse Medical obtained a CE mark to start marketing its Barrel vascular reconstruction device in Europe. Item

> Expectations are that major CMS reimbursement cuts are on their way for image-guided breast biopsies and other medical imaging options, and the fear is that patient outcomes will be harmed as a result. Story

Biotech News

@FierceBiotech: The 5 biggest trends in biopharma R&D in 2013. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: J&J partners up with Orion on a new approach to fighting Alzheimer's--neurotransmitters--a la Lundbeck/Otsuka. News | Follow @JohnCFierce

@DamianFierce: Welcome back, Iclusig. Release | Follow @DamianFierce

@EmilyMFierce: Cells from the eye are inkjet printed for the first time. More | Follow @EmilyMFierce

> Ariad storms back with an FDA nod to get Iclusig back on the U.S. market. Story

> GlycoMimetics gets back on the IPO train with another pitch. More

> Jazz Pharma trades $1B for Gentium and a well-traveled orphan drug. News

Pharma News

@FiercePharma: Top new news Thursday: Bristol bails out of diabetes venture in $4.1B sell-out to AstraZeneca. More | Follow @FiercePharma

@EricPFierce: FDA still has to approve J&J plans to lease part of Ben Venue plant and make Doxil itself. Article | Follow @EricPFierce

@CarlyHFierce: Bad news for AstraZeneca. Appeals court frees Hanmi of double-damage risk for its Nexium copy. Story | Follow @CarlyHFierce

> Actelion will pay $407M in damages for its buyout to protect Tracleer. News

> Jazz will pay $1B for Italy's Gentium, sweeping up another specialty drugmaker. Story

> Doxil update: J&J strikes deal to manufacture Doxil itself at Ben Venue plant. More

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.